Javascript must be enabled to continue!
Persistent bacteremia predicts poor outcomes among neutropenic patients with carbapenem-resistant gram-negative bloodstream infections receiving appropriate therapy
View through CrossRef
Abstract
Purpose
Identifying persistent bacteremia early in patients with neutropenia may improve outcome. This study evaluated the role of follow-up blood cultures (FUBC) positivity in predicting outcomes among patients with neutropenia and carbapenem-resistant gram-negative bloodstream infections (CRGNBSI).
Methods
This retrospective cohort study conducted between December 2017 and April 2022 included patients more than 15 years old with neutropenia and CRGNBSI, who survived for ≥ 48 h, receiving appropriate antibiotic therapy and had FUBCs. Patients with polymicrobial bacteremia within 30 days were excluded. The primary outcome was 30 day mortality. Persistent bacteremia, septic shock, recovery from neutropenia, prolonged or profound neutropenia, requirement of intensive care and dialysis, and initiation of appropriate empirical therapy were also studied.
Results
In our study cohort of 155 patients, the 30 day mortality rate was 47.7%. Persistent bacteremia was common in our patient cohort (43.8%). Carbapenem resistant isolates identified in the study were K.pneumoniae (80%), E.coli (12.26%), P.aeruginosa (5.16%), A.baumanii (1.94%) and E.cloacae (0.65%). The median time for sending a FUBC was 2 days (IQR, 1–3 days). Patients with persistent bacteremia had higher mortality than those without (56.76% versus 32.1%; p < 0.001). Appropriate initial empirical therapy was given to 70.9%. Recovery from neutropenia occurred in 57.4% while 25.8% had prolonged or profound neutropenia. Sixty-nine percent (107/155) had septic shock and needed intensive care; 12.2% of patients required dialysis. Non-recovery from neutropenia (aHR, 4.28; 95% CI 2.53–7.23), presence of septic shock (aHR, 4.42; 95%CI 1.47–13.28), requirement of intensive care (aHR,3.12;95%CI 1.23–7.93), and persistent bacteremia (aHR,1.74; 95%CI 1.05–2.89) significantly predicted poor outcomes in multivariable analysis.
Conclusion
FUBC showing persistent bacteremia predicted poor outcomes among neutropenic patients with carbapenem-resistant gram-negative bloodstream infections (CRGNBSI) and should be routinely reported.
Springer Science and Business Media LLC
Title: Persistent bacteremia predicts poor outcomes among neutropenic patients with carbapenem-resistant gram-negative bloodstream infections receiving appropriate therapy
Description:
Abstract
Purpose
Identifying persistent bacteremia early in patients with neutropenia may improve outcome.
This study evaluated the role of follow-up blood cultures (FUBC) positivity in predicting outcomes among patients with neutropenia and carbapenem-resistant gram-negative bloodstream infections (CRGNBSI).
Methods
This retrospective cohort study conducted between December 2017 and April 2022 included patients more than 15 years old with neutropenia and CRGNBSI, who survived for ≥ 48 h, receiving appropriate antibiotic therapy and had FUBCs.
Patients with polymicrobial bacteremia within 30 days were excluded.
The primary outcome was 30 day mortality.
Persistent bacteremia, septic shock, recovery from neutropenia, prolonged or profound neutropenia, requirement of intensive care and dialysis, and initiation of appropriate empirical therapy were also studied.
Results
In our study cohort of 155 patients, the 30 day mortality rate was 47.
7%.
Persistent bacteremia was common in our patient cohort (43.
8%).
Carbapenem resistant isolates identified in the study were K.
pneumoniae (80%), E.
coli (12.
26%), P.
aeruginosa (5.
16%), A.
baumanii (1.
94%) and E.
cloacae (0.
65%).
The median time for sending a FUBC was 2 days (IQR, 1–3 days).
Patients with persistent bacteremia had higher mortality than those without (56.
76% versus 32.
1%; p < 0.
001).
Appropriate initial empirical therapy was given to 70.
9%.
Recovery from neutropenia occurred in 57.
4% while 25.
8% had prolonged or profound neutropenia.
Sixty-nine percent (107/155) had septic shock and needed intensive care; 12.
2% of patients required dialysis.
Non-recovery from neutropenia (aHR, 4.
28; 95% CI 2.
53–7.
23), presence of septic shock (aHR, 4.
42; 95%CI 1.
47–13.
28), requirement of intensive care (aHR,3.
12;95%CI 1.
23–7.
93), and persistent bacteremia (aHR,1.
74; 95%CI 1.
05–2.
89) significantly predicted poor outcomes in multivariable analysis.
Conclusion
FUBC showing persistent bacteremia predicted poor outcomes among neutropenic patients with carbapenem-resistant gram-negative bloodstream infections (CRGNBSI) and should be routinely reported.
Related Results
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
2679. Factors Associated with Multidrug-resistant Gram-Negative Bacteremia in Acute Leukemia Patients with Neutropenic Fever, a Retrospective Study
2679. Factors Associated with Multidrug-resistant Gram-Negative Bacteremia in Acute Leukemia Patients with Neutropenic Fever, a Retrospective Study
Abstract
Background
Gram--negative bacteremia in acute leukemia patients with neutropenia is associated with high morbidity and ...
Challenging Management of Postoperative Empyema: A Case Report with Literature Review
Challenging Management of Postoperative Empyema: A Case Report with Literature Review
Abstract
Introduction: Pleural empyema is the collection of pus within the pleural cavity, typically arising as a complication of pneumonia, chest trauma, thoracic surgery, or bact...
Comparative Effectiveness of Non-Carbapenem versus Carbapenem Therapy for Serious Infections Caused by AmpC β-Lactamase-Producing Enterobacteriaceae: A Retrospective Cohort Study
Comparative Effectiveness of Non-Carbapenem versus Carbapenem Therapy for Serious Infections Caused by AmpC β-Lactamase-Producing Enterobacteriaceae: A Retrospective Cohort Study
Abstract
Introduction:
AmpC β-lactamase-producing Enterobacteriaceae pose significant therapeutic challenges, with carbapenems traditionally cons...
659. Epidemiology and Clinical Characteristics of Bacteremia Following Portal Vein Embolization
659. Epidemiology and Clinical Characteristics of Bacteremia Following Portal Vein Embolization
Abstract
Background
Portal vein embolization (PVE) is performed to induce liver hypertrophy before major hepatectomy. As ...
Risk Factors and Outcomes of Bacteremia Caused by Carbapenem Resistant Enterobacterales Compared to Carbapenem Susceptible Enterobacterales
Risk Factors and Outcomes of Bacteremia Caused by Carbapenem Resistant Enterobacterales Compared to Carbapenem Susceptible Enterobacterales
Abstract
BackgroundDue to shrinking therapeutic options, infections due to Carbapenem-resistant Enterobacterales (CRE) are an urgent threat in healthcare systems. We compar...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Phenotypic characterization of carbapenem non-susceptible gram-negative bacilli isolated from clinical specimens
Phenotypic characterization of carbapenem non-susceptible gram-negative bacilli isolated from clinical specimens
Background
Multidrug resistant, extremely drug-resistant, pan-drug resistant, carbapenem-resistant, and carbapenemase-producing gram-negative bacteria are becoming more common in h...

